[go: up one dir, main page]

WO2009007334A3 - Transdermale therapeutische systeme, welche den wirkstoff anastrozol enthalten - Google Patents

Transdermale therapeutische systeme, welche den wirkstoff anastrozol enthalten Download PDF

Info

Publication number
WO2009007334A3
WO2009007334A3 PCT/EP2008/058743 EP2008058743W WO2009007334A3 WO 2009007334 A3 WO2009007334 A3 WO 2009007334A3 EP 2008058743 W EP2008058743 W EP 2008058743W WO 2009007334 A3 WO2009007334 A3 WO 2009007334A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
anastrozole
transdermal therapeutic
contain
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/058743
Other languages
English (en)
French (fr)
Other versions
WO2009007334A2 (de
Inventor
Christian Braetter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP08774817A priority Critical patent/EP2178523A2/de
Publication of WO2009007334A2 publication Critical patent/WO2009007334A2/de
Publication of WO2009007334A3 publication Critical patent/WO2009007334A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die Erfindung betrifft ein transdermales therapeutisches System (TTS), welches eine wirkstoffundurchlässige Rückschicht, eine Adhäsivschicht, welche eine Adhäsivkomponenteund den Wirkstoff Anastrozol oder dessen physiologisch verträgliches Hydrat, Solvat oder Salz gelöst in einer Konzentration von 0,1% (m/m) bis 30% (m/m), bezogen auf das Gewicht der Adhäsivschicht, enthält (wirkstoffhaltige Schicht) und eine hautseitige Abziehschicht, welche vor der Applikation des TTS entfernt wird, umfasst. Ebenso betrifft die Erfindung die Verwendung dieses TTS.
PCT/EP2008/058743 2007-07-10 2008-07-07 Transdermale therapeutische systeme, welche den wirkstoff anastrozol enthalten Ceased WO2009007334A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08774817A EP2178523A2 (de) 2007-07-10 2008-07-07 Transdermale therapeutische systeme, welche den wirkstoff anastrozol enthalten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007032468.7 2007-07-10
DE200710032468 DE102007032468A1 (de) 2007-07-10 2007-07-10 Transdermale Therapeutische Systeme, welche den Wirkstoff Anastrozol enthalten

Publications (2)

Publication Number Publication Date
WO2009007334A2 WO2009007334A2 (de) 2009-01-15
WO2009007334A3 true WO2009007334A3 (de) 2009-03-12

Family

ID=40121449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/058743 Ceased WO2009007334A2 (de) 2007-07-10 2008-07-07 Transdermale therapeutische systeme, welche den wirkstoff anastrozol enthalten

Country Status (3)

Country Link
EP (1) EP2178523A2 (de)
DE (1) DE102007032468A1 (de)
WO (1) WO2009007334A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010046464A1 (de) 2009-03-19 2011-04-21 Amw Gmbh Transdermales System mit Aromatasehemmer
DE102010026883A1 (de) 2010-03-11 2011-12-15 Amw Gmbh Transdermales System mit Aromatasehemmer
WO2017054151A1 (zh) * 2015-09-30 2017-04-06 徐静 一种含有阿那曲唑的外用贴剂及其应用
DE102019110397A1 (de) * 2019-04-18 2020-10-22 Amw Gmbh Transdermales Darreichungssystem mit Aromatasehemmer in übersättigter Matrix
DE102019110398A1 (de) * 2019-04-18 2020-10-22 Amw Gmbh Transdermales Darreichungssystem mit Aromatasehemmer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006788A1 (en) * 1995-08-14 1997-02-27 Janssen Pharmaceutica N.V. Transdermal administration of vorozole
WO2002017928A2 (de) * 2000-08-30 2002-03-07 Lts Lohman Therapie-Systeme Ag Transdermales therapeutisches system zur abgabe von exemestan
CN1927190A (zh) * 2006-09-28 2007-03-14 哈尔滨健迪医药技术有限公司 来曲唑透皮给药贴剂及其贴剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE505635C2 (sv) 1995-11-28 1997-09-22 Aga Ab Sätt och anordning för att tillsätta ett luktämne till ett ledningssystem för gas
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
EP0943333A1 (de) 1998-03-18 1999-09-22 S.W. Patentverwertungs GmbH Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
DE60118363T2 (de) * 2000-07-10 2006-12-07 Hormos Medical Ltd. Methoden zur behandlung des kryptorchysmus
CN100374116C (zh) * 2002-07-12 2008-03-12 潘塔希生物科学股份有限公司 用于癌症治疗的含有雌四醇衍生物的药物组合物
US20060189670A1 (en) * 2005-02-22 2006-08-24 Glenmark Pharmaceuticals Limited Process for the preparation of anastrozole and intermediates thereof
WO2007045027A1 (en) * 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006788A1 (en) * 1995-08-14 1997-02-27 Janssen Pharmaceutica N.V. Transdermal administration of vorozole
WO2002017928A2 (de) * 2000-08-30 2002-03-07 Lts Lohman Therapie-Systeme Ag Transdermales therapeutisches system zur abgabe von exemestan
CN1927190A (zh) * 2006-09-28 2007-03-14 哈尔滨健迪医药技术有限公司 来曲唑透皮给药贴剂及其贴剂的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BUZDAR AMAN U; ROBERTSON JOHN F R; EIERMANN WOLFGANG; NABHOLTZ JEAN-MARC: "An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.", CANCER, vol. 95, no. 9, 1 November 2002 (2002-11-01), United States, pages 2006 - 2016, XP002510617 *
DATABASE EPODOC EUROPEAN PATENT OFFICE, THE HAGUE, NL; XP002510618 *
SIPE ET AL: "A prospective randomized trial comparing anastrozole and clomiphene citrate in an ovulation induction protocol using gonadotropins", FERTILITY AND STERILITY, ELSEVIER SCIENCE INC, NEW YORK, NY, US, vol. 86, no. 6, 22 November 2006 (2006-11-22), pages 1676 - 1681, XP005776229, ISSN: 0015-0282 *

Also Published As

Publication number Publication date
WO2009007334A2 (de) 2009-01-15
EP2178523A2 (de) 2010-04-28
DE102007032468A1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2011076621A3 (de) Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
IL213359A0 (en) Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
NZ611920A (en) Percutaneous absorption preparation containing rivastigmine
MY161895A (en) Dermal film-forming liquid formulations for drug release to skin
UA98799C2 (ru) Твердый препарат, включающий алоглиптин и гидрохлорид метформина
WO2010008893A3 (en) Anchor systems and methods
CL2012003229A1 (es) Formulación farmacéutica para aplicación tópica en la piel que comprende una emulsión de aceite en agua y el compuesto (r)-3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]propanonitrilo, inhibidor de jak1/jak2; método para tratar un trastorno de la piel; y su uso en el tratamiento de un trastorno de la piel.
NZ589542A (en) Transdermal drug delivery system comprising an active agent in amorphous form and polyvinylpyrrolidone
CL2009000967A1 (es) Compuesto 4-ciclobutil-n-((2s,5r)-5-hidroxi-2-adamantil)-2-morfolin-4-ilpiridin-5-carboxamida, inhibidor de la enzima 11betahsd1; composicion farmaceutica que lo comprende; y su uso en un procedimiento de tratamiento profilactico o terapeutico de un animal de sangre caliente.
NO20081253L (no) Klebepreparat inneholdende bisopropol
WO2008151040A3 (en) Analgesic coated medical product
IL216176A (en) Derivatives (3'-fluoro-4'-hydroxymethyl-5 '- (methylsulfonyl) biphenyl-4-yl) -2-phenylalkyl- (h1-imidazole-4-yl) propane-2-ol and pharmaceuticals containing them
WO2006091442A3 (en) Transdermal systems having control delivery system
WO2009007334A3 (de) Transdermale therapeutische systeme, welche den wirkstoff anastrozol enthalten
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
SI2529732T1 (sl) Transdermalni terapevtski sistem z adhezivno plastjo, postopek za silikoniziranje hrbtne plasti sistema in uporaba hrbtne plasti
IL198745A0 (en) Transdermal therapeutic system comprising ion fair micro-reservoirs
WO2009030351A3 (de) Transdermales therapeutisches system enthaltend längliche hohlkörper
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
WO2009026135A3 (en) Controlled transdermal bisoprolol delivery system
MX2009008993A (es) Dispositivo para la administracion percutanea de bisoprolol.
NZ584190A (en) Once-a-day replacement transdermal administration of fentanyl
WO2007137732A3 (de) Selbstzerstörendes transdermales therapeutisches system
WO2004069286A3 (de) Für die wärmeanwendung zur beschleunigung der permeation von wirkstoffen geeignetes transdermales therapeutisches system und seine verwendung

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08774817

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008774817

Country of ref document: EP